Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA02 - RET and Novel Combinations of Osimertinib

    • 09:30 - 10:30
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      MA02.02 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

      09:35 - 09:40  |  Presenter: Qing Zhou

      • Abstract

      Loading...

  • +

    FP16 - Tumor Biology and Systems Biology: Basic and Translational Science

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Tumor Biology and Systems Biology: Basic and Translational Science
    • +

      FP16.03 - Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

      00:00 - 00:00  |  Presenter: Myung-Ju Ahn

      • Abstract

      Loading...

  • +

    P01 - Early Stage/Localized Disease/Ablative Therapies - Adjuvant Therapy

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      P01.01 - LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC

      00:00 - 00:00  |  Presenter: Jonathan Goldman

      • Abstract

      Loading...

  • +

    P40 - Multimodality of Advanced Lung Cancer - Clinical Outcomes

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Multimodality of Advanced Lung Cancer
    • +

      P40.02 - Pemetrexed in Advanced-stage Lymphoepithelioma Carcinoma of Lung

      00:00 - 00:00  |  Presenter: Ri-Qiang Liao

      • Abstract

      Loading...

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

    • +

      P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P47.09 - Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2

      00:00 - 00:00  |  Presenter: Christophe Dooms

      • Abstract

      Loading...

  • +

    P49 - Novel Therapeutics and Targeted Therapies - EGFR Major

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P49.01 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC

      00:00 - 00:00  |  Presenter: Song Dong

      • Abstract

      Loading...

  • +

    P51 - Novel Therapeutics and Targeted Therapies - EGFR Resistance

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P51.01 - Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)

      00:00 - 00:00  |  Presenter: Chong Kin Liam

      • Abstract

      Loading...

  • +

    P52 - Novel Therapeutics and Targeted Therapies - KRAS

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P52.02 - High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Hui-Bo Feng

      • Abstract

      Loading...

  • +

    IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the Treatment Journey in NSCLC with Immuno-oncology and EGFR-TKIs

    • 05:15 - 06:15
    • 9/09/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS04.01 - Welcome and Introduction

      05:15 - 05:20  |  Presenter: Yi-Long Wu

      • Abstract

      No abstract available for this presentation